Shares of Fate Therapeutics Inc (NASDAQ:FATE) have earned a consensus recommendation of “Buy” from the eleven ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $14.67.
Several equities research analysts recently issued reports on FATE shares. Raymond James Financial reiterated a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a report on Wednesday, December 13th. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Tuesday, January 9th. ValuEngine downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Piper Jaffray Companies reiterated a “top pick” rating and issued a $20.00 price objective on shares of Fate Therapeutics in a report on Tuesday, March 6th.
Shares of Fate Therapeutics (NASDAQ FATE) opened at $11.72 on Tuesday. The company has a quick ratio of 9.29, a current ratio of 9.29 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $624.26, a price-to-earnings ratio of -11.49 and a beta of 1.65. Fate Therapeutics has a 1-year low of $2.52 and a 1-year high of $14.45.
Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.05). The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.02 million. Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. The company’s revenue was up .0% on a year-over-year basis. research analysts forecast that Fate Therapeutics will post -0.91 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James & Associates acquired a new position in Fate Therapeutics during the 4th quarter worth $141,000. The Manufacturers Life Insurance Company boosted its position in shares of Fate Therapeutics by 61.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 12,686 shares in the last quarter. New York State Common Retirement Fund acquired a new position in shares of Fate Therapeutics during the 2nd quarter worth about $131,000. Russell Investments Group Ltd. acquired a new position in shares of Fate Therapeutics during the 3rd quarter worth about $234,000. Finally, California State Teachers Retirement System acquired a new position in shares of Fate Therapeutics during the 2nd quarter worth about $219,000. 66.43% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/20/fate-therapeutics-inc-fate-given-average-recommendation-of-buy-by-brokerages.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.